AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04160143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection and stereotactic body radiation therapy (SBRT)
Description: Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
Study NCT03146468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
Study NCT00652392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Study NCT00652392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: budesonide and placebo
Study NCT01508546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary dissection
Description: Conservative breast surgery with or without axillary dissection
Study NCT04283266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of synbiotic (Bifidobaterium animalis lactis Vesalius 002 and Fructo-Oligosaccharrides) for 5 days, then they received daily 1 sachet for the next 25 days
Study NCT04283266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Middle-aged subjects, who met ROME III criteria for constipation, received daily two sachets of placebo (maltodextrin and sucrose) for 5 days, then they received daily 1 sachet for the next 25 days
Study NCT04066803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
Study NCT04066803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
Study NCT04066803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
Study NCT04066803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
Study NCT04066803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
Study NCT02815917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FTP PET/CT
Description: All PET/CT imaging sessions will include an injection of \[18F\]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of \[18F\]FTP in healthy volunteers and cocaine-dependent volunteers.
Study NCT01436071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50mcg
Description: Inhalation powder delivered by Novel Dry Powder Inhaler
Study NCT01436071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder delivered by Novel Dry Powder Inhaler
Study NCT04026139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Band Resistance Exercise
Description: Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
Study NCT04026139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active joint range-of-motion exercises and isometric contraction exercises
Description: The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
Study NCT01955122 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tandem Colonoscopy
Description: Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
Study NCT01762176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocolized intensive treatment
Description: Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
Study NCT01762176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
Study NCT02445196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Coach
Description: PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
Study NCT02445196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Coach
Description: PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
Study NCT02445196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Description: All participants must have a smartphone, either apple or android.
Study NCT02445196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone
Description: All participants must have a smartphone, either apple or android.
Study NCT01728220 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled NO delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitric oxide by means of an INOpulse DS-C device using an INOpulse nasal cannula.
Study NCT01728220 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
Study NCT01728220 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo delivered via INOpulse DS-C Device
Description: Subjects will be treated with nitrogen gas by means of an INOpulse DS-C device using an INOpulse nasal cannula.
Study NCT01195545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veritas® Collagen Matrix
Description: biological mesh in hernia repair
Study NCT04264429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrapatellar strap
Description: Orthotic device which is positioned over the patellar tendon
Study NCT04264429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic band
Description: Orthotic device which is positioned over the patellar tendon
Study NCT04586595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REVISiT intervention
Description: REVISiT is a pharmacist-led retrospective review of prescribing followed by a feedback meeting to discuss the review findings.
Study NCT00910351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro, BAYQ3939)
Description: 25 mg inhaled Ciprofloxacin
Study NCT01721005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Subject education to pulse palpation
Description: The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
Study NCT02915471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Peer-to-Peer Support Mentoring
Description: The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
Study NCT01215175 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT01215175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114, Aluminum Adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT01215175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114, Aluminum Nonadjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
Study NCT01028222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
Study NCT01028222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTIC
Description: DTIC was supplied locally as sterile powder for i.v. infusion.
Study NCT00510250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
Study NCT00510250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40mg/m2 administered weekly via IV, with Radiation
Study NCT00510250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
Study NCT00352885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
Study NCT00352885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
Study NCT00352885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
Study NCT00352885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
Study NCT02960113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: scopolamine patch
Description: Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
Study NCT02960113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure point P6
Description: Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
Study NCT03282487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified release hydrocortisone
Description: Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
Study NCT00863109 — intervention group
Intervention type: BIOLOGICAL
Intervention: Peginterferon alfa-2b (PEG)
Description: Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
Study NCT00863109 — intervention group
Intervention type: DRUG
Intervention: Ribavirin (RBV)
Description: Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
Study NCT01437696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
Study NCT01437696 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
Study NCT01437696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No liquid cholecalciferol will be added to the food.
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa (Org 36286)
Description: 100 µg corifollitropin alfa subcutaneous (SC) injection
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recFSH (follitropin beta)
Description: 150 IU recFSH SC injection
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonadatropin releasing hormone (GnRH) antagonist (ganirelix)
Description: GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC
Study NCT00702845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: progesterone
Description: Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Study NCT00702845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: progesterone
Description: Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-recFSH (follitropin alfa)
Description: Placebo-recFSH administered at the equivalent volume of 150 IU/day.
Study NCT00702845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
Study NCT00702845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: open-label recFSH
Description: Open-label recFSH administered up to a maximum dose of 200 IU/day.
Study NCT00702845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: open-label recFSH
Description: Open-label recFSH administered up to a maximum dose of 200 IU/day.
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 24mg and 6 mg iv infusion
Description: I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 12.5mg capsule
Description: 12.5mg oral immediate release capsule
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 48 mg and 11 mg iv infusion
Description: I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452 25mg capsule
Description: 25mg oral immediate release capsule
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo iv infusion
Description: Matching placebo iv infusion
Study NCT00682565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo oral immediate release capsule
Study NCT03513510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iChoose
Study NCT04094896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Study NCT04094896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCHP
Description: Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
Study NCT02039726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: 20 or 30 mg quizartinib tablets administered orally once daily
Study NCT02039726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvage Chemotherapy
Description: Low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA) administered during 28-day cycles
Study NCT01504256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)
Study NCT01504256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil, leucovorin, oxaliplatin, docetaxel
Description: FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)
Study NCT04013516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentive
Description: During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.